Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Researchers noted fDPP-4 discriminated clinical activity from remission with areas under the curve of 0.8 (95% CI, 0.68-0.93) and 0.76 (95% CI, 0.58-0.94) in patients with UC and CD, respectively.

Dipeptidyl peptidase 4 (DPP-4) is a homodimeric type II transmembrane receptor identical to the leukocyte surface antigen CD26 and is also present in a soluble, enzymatically active form in plasma ...

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes may cause joint pain so intense it is disabling, the US Food and Drug Administration (FDA) warned today. Fortunately, the pain goes ...

As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain.

Most patients in the DPP-4 cohort received sitagliptin (94.6%), although saxagliptin and vildagliptin were also prescribed in 5.4% and less than 0.1% of patients, respectively.

Across a broad swath of patients, short-term use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor appears to reduce the risk of major adverse cardiovascular events, most notably cardiovascular ...

Results showed that DPP-4 inhibitors yielded 0.42 cases of bullous pemphigoid per 1,000 person-years compared with 0.31 cases per 1,000 person-years for sulfonylureas (HR = 1.42; 95% CI, 1.17-1.72).

Summary A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data ...

This study evaluates the long-term cost-effectiveness of treatment involving combination therapy with dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2 ...